Pam Crotty

Ms. Pam Crotty

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in Hepatology Communications
Verified
Journal Article
Open access
Carla S. CoffinCarla S. Coffin
Carla S. Coffin
JVJordyn Vienneau
Jordyn Vienneau
CCCurtis Cooper
Curtis Cooper
KDKaren E. Doucette
Karen E. Doucette
MEMagdy Elkashab
Magdy Elkashab
COCarla Osiowy
Carla Osiowy

22 August 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
RGReanna George
Reanna George
GEGeoff Eaton
Geoff Eaton
PCPam Crotty
Pam Crotty
CHCheryl A Heykoop
Cheryl A Heykoop
NDNorma D'Agostino
Norma D'Agostino
SGSheila Nadine Garland
Sheila Nadine Garland
Adolescents and young adults (AYAs) diagnosed with cancer between the ages of 15 and 39 years face unique challenges that impact their long-term quality of life (QoL). Physical functioning, relationship status, social support, anxiety, and depression have been associated with QoL in AYAs with cancer. This study explored factors associated with increased QoL in a sample of 392 AYAs with cancer in Canada who participated in the initial Young Adult Cancer Canada RECOVER survey. The EORTC QLQ-C30 was used to measure QoL. Adjusting for relevant demographic, cancer, and clinical variables, the only factors significantly associated with QoL in multivariable analysis were symptoms of depression [Mild (β = −0.420, p < 0.001); Moderate (β = −0.937, p < 0.001); Moderately Severe (β = −1.188, p < 0.001); Severe (β = −2.182, p < 0.001)] and generalized anxiety [Mild (β = −0.244, p = 0.012); Moderate (β = −0.420, p = 0.002); Moderately severe (β = −0.400, p = 0.012); Severe (β = −0.697, p = 0.010)], as well as having completed treatment (β = −0.347, p < 0.001). Age, gender, time since diagnosis, having children, education, income, fear of recurrence, and social support were not significantly associated with QoL. These results support the need for age-appropriate resources to help AYAs manage the long-term psychological impacts of cancer.

11 August 2026 in Liver International
Verified
Journal Article
Open access
PDF file
HKHinhin Ko
Hinhin Ko
JVJordyn Vienneau
Jordyn Vienneau
CCCurtis L. Cooper
Curtis L. Cooper
PCPam Crotty
Pam Crotty
SCStephen Congly
Stephen Congly
Carla S. CoffinCarla S. Coffin
Carla S. Coffin
Background & Aims: Chronic hepatitis B (CHB) remains a leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, yet treatment uptake is suboptimal even in high‐resource settings. This pan‐Canadian study aimed to quantify treatment gaps within the Canadian Hepatitis B Network (CanHepB) Registry, compare characteristics of treatment‐eligible but untreated patients to those receiving therapy, and assess patient and specialist perspectives on barriers to treatment. Methods: A cross‐sectional, retrospective analysis of 1983 adults with CHB followed in 18 Canadian hepatitis B specialty clinics between January 2018 and November 2024. Treatment eligibility was determined using the 2018 Canadian Association for the Study of the Liver guidelines. An anonymous survey captured patient‐reported barriers and perspectives ( n = 191), while a separate survey evaluated specialist perceptions ( n = 54). Results: Among 881 untreated patients, 46.4% ( n = 409) were treatment eligible. Compared with the treatment group ( n = 1087), the treatment‐eligible but untreated patients were younger (median 47.3 vs. 54.5 years), more frequently female (54.2% vs. 39.7%), and more likely to be of Black/African/Caribbean origin (18.2% vs. 9.7%). They had a lower prevalence of cirrhosis (2.4% vs. 20.3%), HCC (0.7% vs. 9.3%), and hypertension (17.1% vs. 22.9%), but a higher prevalence of steatotic liver disease (36.4% vs. 24.6%) and dyslipidemia (14.7% vs. 10.8%). Among untreated respondents, concerns included side effects, the need for long‐term therapy, and lack of curative options. Conversely, specialists identified cost as the primary barrier and side effects as the least concerning. Conclusion: This nationwide study reveals a significant treatment gap in CHB care, driven by demographic disparities and a mismatch between patient concerns and clinician perceptions.